Safety and Immunogenicity of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2015
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 24 Feb 2011 Actual end date (1 Feb 2013) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Actual initiation date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.